GI Innovation partners with MSD for clinical trials combining immunotherapy agents

By Kim Joo-heon Posted : August 26, 2024, 11:39 Updated : August 26, 2024, 15:09
이미지 확대
Courtesy of GI Innovation
Courtesy of GI Innovation
SEOUL, August 26 (AJU PRESS) - Korea's pharmaceutical company GI Innovation announced Monday it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with American multinational pharmaceutical firm Merck & Co.

Under the agreement, the two companies will evaluate the efficacy of combining GI Innovation's immunotherapy agent GI-102 with MSD's immunotherapy drug Keytruda in clinical trials involving patients with resistant liver cancer, melanoma, and kidney cancer.

GI-102 is described by GI Innovation as a therapeutic agent with the ability to increase the number of immune cells by an average of five times, demonstrating potent immune cell proliferation capabilities.
Kim Joo-heon Reporter
Kim Joo-heon

Copyright ⓒ Aju Press All rights reserved.

0 comments
0 / 300

Are you sure you want to delete this comment?

Close

You can write comments after logging in.
Do you want to log in?

Close

You have already participated.

Close

Related

기사 이미지 확대 보기
닫기